NO20025358L - Ortosubstituerte antranilsyreamider og deres anvendelse som legemidler - Google Patents

Ortosubstituerte antranilsyreamider og deres anvendelse som legemidler

Info

Publication number
NO20025358L
NO20025358L NO20025358A NO20025358A NO20025358L NO 20025358 L NO20025358 L NO 20025358L NO 20025358 A NO20025358 A NO 20025358A NO 20025358 A NO20025358 A NO 20025358A NO 20025358 L NO20025358 L NO 20025358L
Authority
NO
Norway
Prior art keywords
acid amides
anthranilic acid
orthosubstituted
drugs
ortho
Prior art date
Application number
NO20025358A
Other languages
English (en)
Other versions
NO20025358D0 (no
NO323541B1 (no
Inventor
Martin Krueger
Andreas Huth
Orlin Petrov
Dieter Seidelmann
Karl-Heinz Thierauch
Martin Haberey
Andreas Menrad
Alexander Ernst
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20025358D0 publication Critical patent/NO20025358D0/no
Publication of NO20025358L publication Critical patent/NO20025358L/no
Publication of NO323541B1 publication Critical patent/NO323541B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20025358A 2000-05-09 2002-11-08 Ortosubstituerte antranilsyreamider og deres anvendelse for fremstilling av legemidler NO323541B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10023486A DE10023486C1 (de) 2000-05-09 2000-05-09 Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
PCT/EP2001/005214 WO2001085719A1 (de) 2000-05-09 2001-05-08 Ortho substituierte anthranilsäureamide und deren verwendung als arzneimittel

Publications (3)

Publication Number Publication Date
NO20025358D0 NO20025358D0 (no) 2002-11-08
NO20025358L true NO20025358L (no) 2002-11-08
NO323541B1 NO323541B1 (no) 2007-06-11

Family

ID=7641923

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025358A NO323541B1 (no) 2000-05-09 2002-11-08 Ortosubstituerte antranilsyreamider og deres anvendelse for fremstilling av legemidler

Country Status (31)

Country Link
US (2) US7081468B2 (no)
EP (1) EP1280799B1 (no)
JP (1) JP2003532725A (no)
KR (1) KR20020094024A (no)
CN (1) CN1237062C (no)
AT (1) ATE258174T1 (no)
AU (2) AU7400101A (no)
BG (1) BG107261A (no)
BR (1) BR0110621A (no)
CA (1) CA2407852A1 (no)
CZ (1) CZ20023677A3 (no)
DE (2) DE10023486C1 (no)
DK (1) DK1280799T3 (no)
EE (1) EE04938B1 (no)
ES (1) ES2214424T3 (no)
HK (1) HK1056728A1 (no)
HR (1) HRP20020977B1 (no)
HU (1) HUP0301954A2 (no)
IL (2) IL152578A0 (no)
MX (1) MXPA02010915A (no)
NO (1) NO323541B1 (no)
NZ (1) NZ521700A (no)
PL (1) PL358204A1 (no)
PT (1) PT1280799E (no)
RU (1) RU2264399C2 (no)
SK (1) SK15882002A3 (no)
TR (1) TR200400912T4 (no)
UA (1) UA73187C2 (no)
WO (1) WO2001085719A1 (no)
YU (1) YU82702A (no)
ZA (1) ZA200209896B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10023484A1 (de) * 2000-05-09 2001-11-22 Schering Ag Anthranylamide und deren Verwendung als Arzneimittel
DE10023486C1 (de) * 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20030134836A1 (en) * 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
BR0313122A (pt) * 2002-07-31 2005-07-05 Schering Ag Antranilamidopiridinas inibidoras de vegfr-2 e vegfr-3
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
EP1628661A2 (en) * 2003-06-05 2006-03-01 Vertex Pharmaceuticals Incorporated Modulators of vr1 receptor
US7202260B2 (en) 2003-06-13 2007-04-10 Schering Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
DE10327719A1 (de) * 2003-06-13 2005-01-20 Schering Ag VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone
AU2004276341B2 (en) 2003-09-23 2011-04-14 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
DE102004009238A1 (de) * 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
US7427390B2 (en) * 2004-03-10 2008-09-23 Schering Ag Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy
DE102004011720B4 (de) * 2004-03-10 2008-04-03 Bayer Schering Pharma Aktiengesellschaft Radiohalogenierte Benzamidderivate und deren Verwendung in der Tumordiagnostik und Tumortherapie
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1655295A1 (en) * 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
EP1657241A1 (en) * 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US8247556B2 (en) 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
US8106190B2 (en) 2005-11-30 2012-01-31 Astellas Pharma Inc. 2-aminobenzamide derivatives
NZ722019A (en) 2014-01-13 2022-07-01 Aurigene Discovery Tech Ltd Bicyclic heterocyclyl derivatives as irak4 inhibitors
SG11201610009XA (en) * 2014-06-20 2017-01-27 Aurigene Discovery Tech Ltd Substituted indazole compounds as irak4 inhibitors
WO2018178947A2 (en) 2017-03-31 2018-10-04 Aurigene Discovery Technologies Limited Compounds and compositions for treating hematological disorders
AU2018359248B2 (en) 2017-10-31 2023-06-01 Curis, Inc. Compounds and compositions for treating hematological disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3409668A (en) * 1964-11-07 1968-11-05 Palazzo Giuseppe Substituted anthranilamides and process for the preparation thereof
FR2689508B1 (fr) * 1992-04-01 1994-06-17 Fournier Ind & Sante Derives de l'imidazole, leur procede de preparation et leur application en therapeutique.
UA71587C2 (uk) * 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
DE10023484A1 (de) * 2000-05-09 2001-11-22 Schering Ag Anthranylamide und deren Verwendung als Arzneimittel
DE10023492A1 (de) * 2000-05-09 2001-11-22 Schering Ag Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel
DE10023486C1 (de) * 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
DE50213703D1 (de) * 2001-05-08 2009-09-03 Bayer Schering Pharma Ag Selektive anthranylamidpyridinamide als vegfr-2 und vegfr-3 inhibitoren
US20040039019A1 (en) * 2002-06-19 2004-02-26 Schering Ag Selected anthranilaminde pyridinamides and their use as pharmaceutical agents
US7517894B2 (en) * 2002-07-31 2009-04-14 Bayer Schering Pharma Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
US7615565B2 (en) * 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
US7202260B2 (en) * 2003-06-13 2007-04-10 Schering Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
US7659242B2 (en) * 2004-07-19 2010-02-09 Thia Medica As Composition comprising protein material and compounds comprising non-oxidizable fatty acid entities
EP1655295A1 (en) * 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US7906533B2 (en) * 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1657241A1 (en) * 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US20060266770A1 (en) * 2005-05-26 2006-11-30 Fitzgerald Robert M Portable dispensers comprising a mobile dispenser and mobile storage cartridge

Also Published As

Publication number Publication date
BR0110621A (pt) 2003-03-25
CN1237062C (zh) 2006-01-18
PL358204A1 (en) 2004-08-09
IL152578A (en) 2008-11-03
IL152578A0 (en) 2003-05-29
NO20025358D0 (no) 2002-11-08
RU2264399C2 (ru) 2005-11-20
CN1427837A (zh) 2003-07-02
MXPA02010915A (es) 2003-07-14
US20040102441A1 (en) 2004-05-27
EE200200625A (et) 2004-04-15
AU7400101A (en) 2001-11-20
ATE258174T1 (de) 2004-02-15
DK1280799T3 (da) 2004-05-10
CZ20023677A3 (cs) 2003-02-12
WO2001085719A9 (de) 2001-12-27
DE50101364D1 (de) 2004-02-26
ZA200209896B (en) 2004-03-05
JP2003532725A (ja) 2003-11-05
WO2001085719A1 (de) 2001-11-15
AU2001274001B2 (en) 2007-01-18
HRP20020977B1 (en) 2008-05-31
BG107261A (bg) 2003-06-30
US20060014747A1 (en) 2006-01-19
SK15882002A3 (sk) 2003-08-05
NO323541B1 (no) 2007-06-11
EP1280799B1 (de) 2004-01-21
PT1280799E (pt) 2004-06-30
KR20020094024A (ko) 2002-12-16
EP1280799A1 (de) 2003-02-05
HK1056728A1 (en) 2004-02-27
DE10023486C1 (de) 2002-03-14
ES2214424T3 (es) 2004-09-16
HRP20020977A2 (en) 2005-02-28
EE04938B1 (et) 2007-12-17
NZ521700A (en) 2005-09-30
TR200400912T4 (tr) 2004-07-21
US7081468B2 (en) 2006-07-25
UA73187C2 (en) 2005-06-15
CA2407852A1 (en) 2001-11-15
HUP0301954A2 (hu) 2003-09-29
YU82702A (sh) 2006-05-25

Similar Documents

Publication Publication Date Title
NO20025358L (no) Ortosubstituerte antranilsyreamider og deres anvendelse som legemidler
NO20051966L (no) Nye pyrimidinamidderivater og anvendelse derav
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
EE200300212A (et) Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
DK1178958T3 (da) N-cyanomethylamider som proteaseinhibitorer
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
MA26901A1 (fr) Nouvelle composition pharmaceutique
CY1110521T1 (el) Υποκατεστημενα ινδολια για τη διαμορφωση της nfkb-ενεργοτητας
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
NO20055173L (no) Farmasoytisk kombinasjonsblanding omfattende modafinil og et annet legemiddel
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
NO20023551D0 (no) Ibuprofen-inneholdende aktivt middel-preparat
SE0102440D0 (sv) New compound
HUP0200152A2 (hu) KQT1 csatornák gátlóinak alkalmazása parazita férgek és ektoparaziták által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
BR0012291A (pt) Fenoxifluorpirimidinas
SE0004827D0 (sv) Therapeutic compounds
DK1232173T3 (da) Nye fusidinsyrederivater
SE0300535D0 (sv) Treatment of burns
NO20032035D0 (no) Terapeutiske midler for heratokonjunktivitis sykdommer omfattende farnesyleddiksyre som aktiv ingrediens
EA200500538A1 (ru) Фармацевтическое средство для эндоназального применения при лечении болезней и нарушений нервной системы
DK1330253T3 (da) Anvendelse af bioaktiv fraktion af kourindestillat ("Go-mutra") som en biofremmer for antiinfektionsmidler, anticancermidler og næringsmidler
DK1379253T3 (da) Fremgangsmåde til fremstilling og anvendelse af farmaceutiske formuleringer omfattende 7alfa, 11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-on og 17-estere heraf
NO20013901L (no) Umettede kolestanderivater og deres anvendelse for fremstilling av meioseregulerende medikamenter
UA38418A (uk) Засіб для стимуляції регенеративних процесів в інсулінпродукуючому апараті підшлункової залози